- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01963364
Pilot Study of the Effect of Fructans on Fermentation in the Colon & Transit (PERFECT)
A Pilot Study Using Magnetic Resonance Imaging to Measure the Effect of Dietary Supplementation With Fructans on Whole Gut Transit Time, Colonic Gas Volume, and Volume Change in Response to a Fructan Challenge
Some carbohydrates (complex sugars) which are found in grains, fruit and vegetables, cannot be digested by humans. When eaten they pass through the small bowel to the large bowel, or colon. Some bacteria that live in the colon are able to digest these carbohydrates, and use them as an energy source. This releases energy that humans can absorb, and may have other effects on health as well. The process also releases gases such as hydrogen and methane into the colon, which will eventually be released as flatulence.
There is some evidence in animals, and humans, that changing the carbohydrate content of the diet may increase the numbers of bacteria in the colon that can use this energy source. Recent work has looked at how changes in colon bacteria and carbohydrate in the diet affect transit, the speed at which food and stool moves through the stomach and bowels. This undergraduate project will use techniques in Magnetic Resonance Imaging developed in Nottingham to investigate how a prolonged change in dietary carbohydrate might affect speed of transit through the bowel and gas production in the colon, and whether there is any evidence of a change in the level of signalling chemicals that may affect bowel function.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nottingham, United Kingdom, Ng7 2UH
- Nottingham Digestive Diseases Centre
-
Nottingham, United Kingdom, NG7 2RD
- Sir Peter Mansfield Magnetic Resonance Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18-55
- Able to give informed consent
- Does not meet criteria for diagnosis of IBS on Rome III questionnaire
Exclusion Criteria:
- Unable to abstain from smoking for the duration of the study (may affect breath hydrogen readings)
- Self-declared vegetarian, vegan or kosher/ halal diet who cannot eat carmine red dye
- Pregnancy declared by candidate
- Female patients during their menstrual period
- History declared by the candidate of pre-existing gastrointestinal disorder, including but not limited to:
- Inflammatory Bowel Disease
- Coeliac Disease
- Pancreatitis
- Gallstone disease (biliary colic, cholecystitis)
- Diverticulitis
- Cancer of the gastrointestinal tract
- Irritable Bowel Syndrome
- Reported history of previous resection of any part of the gastrointestinal tract other than appendix or gallbladder
- Intestinal stoma
- Any medical condition making participation potentially compromising participation in the study e.g. diabetes mellitus, respiratory disease limiting ability to lie in the scanner
- Contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury
- Reported alcohol dependence
- Unable to stop drugs known to alter GI motility including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists during or in the 2 weeks prior to the test. (Selective serotonin reuptake inhibitors and low dose tricyclic antidepressants will be recorded but will not be an exclusion criteria)
- Antibiotic or probiotic treatment in the past 4 weeks
- Inability to lie flat or exceed scanner limits of weight <120kg
- Poor understanding of English language
- Participation in night shift work the week prior to the study day. Night work is defined as working between midnight and 6.00 AM
- Strenuous exercise greater than 10 hours per week (i.e. no competition training the week prior to the study).
- Participation in any medical trials for the past 3 months
- Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g. cognitive dysfunction, chaotic lifestyle related to substance abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention group
All healthy volunteers
|
On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.
Other Names:
Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses.
The 14th dose of the week is the inulin challenge consumed as part of study day 1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in whole gut transit time after one week (measured in hours) calculated using MRI marker capsule technique
Time Frame: Difference (Delta) between baseline and after one week of intervention
|
5 markers pills will be swallowed 24 hours before MRI scanning.
Each pill will be given a score 0-9 based on the colonic segment where it is located.
The weighted mean of these scores will be the geometric centre.
Previous validation allows a transit time to be calculated from the geometric centre.
|
Difference (Delta) between baseline and after one week of intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in fasting colonic volume
Time Frame: Baseline and after one week of intervention
|
Calculated from segmentation on MRI scans
|
Baseline and after one week of intervention
|
Change in colonic volume 8 hours after ingestion of 40 grams inulin dissolved in 500ml water flavoured with lime juice, measured in millilitres
Time Frame: Baseline and after one week of intervention
|
Calculated from segmentation on MRI scans
|
Baseline and after one week of intervention
|
Change in fasting colonic gas volume, measured in millilitres
Time Frame: Baseline and after one week of intervention
|
Measured using MRI segmentation technique
|
Baseline and after one week of intervention
|
Change in colonic gas volume 8 hours after ingestion of 40 grams inulin dissolved in 500ml water flavoured with lime juice, measured in millilitres
Time Frame: Baseline and after one week of intervention
|
Calculated from segmentation on MRI scans
|
Baseline and after one week of intervention
|
Change in breath hydrogen concentration, measured in parts per million before, 4 hours after, and 8 hours after ingestion of 40 grams inulin
Time Frame: Baseline and after one week of intervention
|
Baseline and after one week of intervention
|
|
Change in faecal 5-HIAA concentration in μmol/g
Time Frame: baseline and after one week of intervention
|
measured by high performance liquid chromatography
|
baseline and after one week of intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of clinically important digestive symptoms during study day or intervention week
Time Frame: one week of intervention
|
|
one week of intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Giles Major, MD, University of Nottingham
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 11072013SCSMRI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Evidence of Adaptation to Dietary Exposure to Fructans
-
Tommaso GoriCompletedExposure of Member of Staff to Medical Diagnostic X-RayGermany
-
State University of New York at BuffaloCompletedExposure to Environmental Pollution | Adverse Effect of Unspecified General Anesthetic
-
London School of Hygiene and Tropical MedicineUniversity of Colorado, Boulder; Ministry of Health, Rwanda; Portland State University and other collaboratorsCompletedFocus of Study is to Assess Filter and Stove Use and Efficacy in Reducing Exposure to Waterborne and Airborne PathogensRwanda
-
Environmental Protection Agency (EPA)CompletedExposure to Pollution | Inhalation of OzoneUnited States
-
GlaxoSmithKlineCompletedRotavirus Infection | Evidence of PCV-1 Replication and/or Immune Response to the PCV-1 in HRV Vaccinated Infants
-
University Clinical Centre, GdanskNutricia FoundationUnknownQuality of Life | Metastatic Colorectal Cancer | Toxicity Due to Chemotherapy | Dietary Modification | Cancer CachexiaPoland
-
University Hospital, CaenNot yet recruitingTo Reduce Duration of Antibiotics Exposure in Patients With COPD Hospitalized in Intensive Care Unit With PneumoniaFrance
-
Rennes University HospitalCompletedHistory of Exposure to Silica or Asbestosis | Positive Testing for ANA as a Marker of Systemic Autoimmune DiseasesFrance
-
Kyberg Vital GmbHCompletedto Improve the Effectiveness of a Amino Acid Dietary Supplement in Chronic Pharyngeal Infections vs PlaceboGermany
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaboratorsRecruitingMitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditionsUnited States, Australia
Clinical Trials on Inulin challenge
-
Scottish Universities Environmental Research CentreUniversity of Glasgow; NHS Greater Clyde and GlasgowCompletedObesity | OverweightUnited Kingdom
-
Eskisehir Osmangazi UniversityUnknownFunctional Constipation
-
Maastricht University Medical CenterCompleted
-
Lund UniversityFood for Health Science Centre, Lund UniversityCompleted
-
University of Illinois at Urbana-ChampaignRenal Research InstituteCompletedBone Diseases, Endocrine | Nutritional and Metabolic DiseasesUnited States
-
Imperial College LondonUniversity of GlasgowCompletedAppetite Regulation | Healthy Obesity, MetabolicallyUnited Kingdom
-
Joslin Diabetes CenterImmusanT, Inc.CompletedType 1 Diabetes | Celiac DiseaseUnited States
-
Emory UniversityCenters for Disease Control and PreventionCompleted
-
Mahidol UniversityCompletedFood (Shrimp) AllergyThailand
-
Hospital Mutua de TerrassaCompletedCeliac Disease | Non-celiac Gluten Sensitivity